Tissue factor pathway inhibitor 2 (TFPI-2) is a 32-kDa extracellular matrix-associated kunitz-type
serine proteinase inhibitor. It is secreted by all vascular cells and plays a role in
tumor invasion and
metastasis, presumably by
plasmin-mediated matrix remodeling. Previous studies have shown high expression of
TFPI-2 by benign
tumors and low or absent expression in highly malignant
tumors.
Malignant meningiomas constitute 10-15% of all
meningiomas and our previous studies revealed loss of expression of
TFPI-2 in
malignant gliomas. To investigate the role of
TFPI-2 in the invasiveness of
malignant meningiomas, we stably transfected the human
meningioma cell line, IOMM-Lee, with a vector capable of expressing a transcript complementary to the full length of
TFPI-2 mRNA in a sense orientation. Restoration of
TFPI-2 led to decreased invasiveness of transfected cells compared to parental and vector controls in
Matrigel and spheroid assays and inhibition of angiogenesis in in vitro co-cultures with human umbilical vein endothelial cells (HUVEC) and in vivo dorsal skin assay studies. As assessed by Western blotting, we also observed increased expression of BAX,
cytochrome c and
caspase 3 as well as decreased expression of XIAP (X-linked inhibitor of apoptosis). Finally,
TFPI-2 overexpression inhibited intracranial
tumor formation in nude mice. Our data substantiate our previous observation that
TFPI-2 plays an important role in
tumor progression and has potential in anti-
cancer therapy.